Daniel K. Spiegelman


Spiegelman most recently stepped down as EVP and CFO of BioMarin Pharmaceuticals Inc. after eight years.  He remains as a senior advisor until September, 2020. His career at BioMarin spanned 17 years.  He served as a CFO in several diversified biotechnology companies over the past 30 years. 

  • 2020 Third Quarter

Added to: Myriad Genetics Inc. - Salt Lake City, UT

Myriad Genetics is a molecular diagnostic company. Revenues are $639 million.